Investment ProfessionalsBB Biotech AG
ISIN-No.: CH0038389992
YTD: 7.61%
Active share: 81.94
Anzahl Positionen: 31
New innovative drugs and technologies are powering sustainable momentum in the biotech sector
Focus on profitable companies and small and mid-cap companies with strong pipelines
Attractive dividend policy; Dividend payment of 5% p.a.
Indexed performance (as at: 20.01.2025)
Share price: EUR 40.30 (20.01.2025)
NAV: EUR 46.30 (20.01.2025)
Rolling performance (20.01.2025)
| Share Price | NAV | Benchmark | |
| 19.01.2024 - 19.01.2025 | -5.72% | 3.89% | 3.50% |
| 19.01.2023 - 19.01.2024 | -20.53% | 0.26% | 2.65% |
| 19.01.2022 - 19.01.2023 | -4.02% | 13.24% | 8.63% |
| 19.01.2021 - 19.01.2022 | -7.70% | -30.83% | -13.22% |
Annualized performance (20.01.2025)
| Share Price | NAV | Benchmark | |
| 1 year | -5.72% | 3.89% | 3.50% |
| 3 years | -10.41% | 5.66% | 3.71% |
| 5 years | -3.29% | 2.14% | 4.75% |
| 10 years | 3.37% | 3.26% | 4.45% |
| Since Inception p.a. | 11.00% | 11.55% | 10.69% |
Cumulative performance (20.01.2025)
| Share Price | NAV | Benchmark | |
| 1M | 6.85% | 3.81% | -1.73% |
| YTD | 8.28% | 4.28% | 0.56% |
| 1 year | -5.72% | 3.89% | 3.50% |
| 3 years | -28.09% | 17.95% | 11.53% |
| 5 years | -15.39% | 11.18% | 26.10% |
| 10 years | 39.25% | 37.85% | 54.53% |
| Since Inception | 1'597.07% | 1'842.23% | 1'470.63% |
Annual performance
| Share Price | NAV | Benchmark | |
| 2024 | -14.08% | 1.71% | 6.30% |
| 2023 | -15.21% | -1.29% | 1.26% |
| 2022 | -19.00% | -6.72% | -4.46% |
| 2021 | 13.34% | -7.79% | 7.39% |
Facts & Key figures
Investment Focus
BB Biotech actively invests worldwide in fast growing companies developing and marketing innovative biotech drugs. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Show moreShow less
Investment suitability & Risk
Low risk
High risk
General Information
| Investment Manager | Bellevue Asset Management AG |
| Custodian | Bank Julius Bär AG |
| Fund Administrator | Bellevue Asset Management AG |
| Auditor | Deloitte AG |
| Launch date | 09.11.1993 |
| Year end closing | 31. Dec |
| Management Fee | 1.10% |
| ISIN number | CH0038389992 |
| Valor number | 3838999 |
| Bloomberg | BBZA GY Equity |
| WKN | A0NFN3 |
Legal Information
| Legal form | Incorporate company |
| SFDR category | Article 8 |
Key data (31.12.2024, base currency CHF)
| Beta | 1.33 |
| Volatility | 31.86 |
| Tracking error | 14.79 |
| Active share | 81.94 |
| Correlation | 0.91 |
| Sharpe ratio | -0.09 |
| Information ratio | 0.06 |
| Jensen's alpha | 2.21 |
| No. of positions | 31 |
Portfolio as at 30.09.2024
Positions
Market capitalization
Breakdown by sector
Currency
Benefits & Risks
Benefits
- Unique opportunity for European investors to access the global biotech sector, a non-cyclical growth industry that is strongly supported by increasing demand, driven by demographic trends and life style changes.
- New innovative drugs and technologies are powering sustainable momentum in the biotech sector.
- Focus on a diversified portfolio of profitable companies as well as small and midcap companies with strong pipelines.
- Management Team with strong scientific and medical expertise. Renowned Board of Directors.
- Attractive dividend policy; Dividend payment of 5% p.a.
Risks
- BB Biotech actively invests in equities. Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
- Biotech equities can be subject to sudden substantial price movements owning to market, sector or company factors.
- BB Biotech invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The price investors pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company.
- BB Biotech may take a leverage of up to 15%, which may lead to even higher price movements compared to the underlying market.
Review / Outlook
December was a challenging month for most stock markets. Rising US treasury yields had been catching investors´ attention. Higher yields are hampering growth stocks and this happened in December.
Biotech stocks were no exception to the downward trend and traded down substantially in December. Vertex disappointed the market with data from its pain drug program. On the other hand we also saw positive news from some biotech companies in December including drug approvals from a number of BB Biotech’s portfolio companies,
Please find below selected highlights from a few of BB Biotech´s portfolio companies in December:
Vertex (-14.0%, in USD) announced on December 20 results from its Phase II study of suzetrigine in people with painful lumbosacral radiculopathy (LSR). The study met its primary endpoint with statistically significant and clinically meaningful reduction in pain on the numeric pain rating scale (NPRS). However, the study also included a placebo reference arm which showed a similar within-group reduction from baseline in pain and this was perceived negatively by the stock market. The study was not designed nor powered for statistical comparison between suzetrigine and placebo.
Neurocrine (+7.7%, in USD) announced on December 13 that the U.S. Food and Drug Administration has approved Crenessity capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH). It is a breakthrough in the treatment landscape for classic CAH.
Agios (-44.7%, in USD) presented on December 8 positive results from the Phase III ENERGIZE-T study investigating mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia. These findings were shared in an oral presentation (abstract #409) at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California. However, the company also reported unexpexted liver injuries in some patients and these saftey findings were perceived negatively by the stock market and the share traded down substantially on the news.
Ionis (-2.2%, in USD) announced on December 19 that the FDA has approved Tryngolza as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). Tryngolza is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS.
Dokumente
Show moreShow less
